The marriage of two innovative technologies—one developed by Northeastern’s Slava Epstein—could accelerate both the discovery of new antibiotics that kill pathogens without encountering resistance and the diagnosis of specific pathogens causing disease, which would enable fast, targeted treatments.
A team led by University Distinguished Professor of Biology Kim Lewis received a five-year, $9 million grant from the National Institute of Health’s National Institute of Allergy and Infectious Diseases to launch a novel platform for developing antibiotics that kill pathogens without encountering resistance.
Slava Epstein’s cutting edge research on microbes is highlighted in The New Yorker.
Northeastern researcher Kim Lewis and his team have launched an all-out effort to find a cure for Lyme disease, which afflicts nearly 300,000 new people in the U.S. each year. Their efforts aim to bring relief to all patients, including those who suffer from a debilitating chronic version of the disease.
When Slava Epstein first arrived in America, he had little more than his family, a smuggled cat, and an “enormous amount of data” from his research in Russia. In 2015, he was part of one of the world’s biggest scientific stories.
A deep read about Professor Slava Epstein’s research, discoveries, and painting skills.
Each year for the past seven years, Foreign Policy selected the leading Global Thinkers whose contributions and work have changed lives and are shaping the world.
“Professor Slava Epstein says the technology that led to the discovery of teixobactin could be used to unearth thousands of medically useful microbes,” writes the CMAJ.
Born from soil, the novel compound made possible by Northeastern researchers’ pioneering work is making headlines around the world.
A few years ago, biologists Slava Epstein and Yoshiteru Aoi fantasized about a device that would work like a highway lane closure to isolate pure bacterial samples from the environment. They teamed with assistant professor of chemical engineering Ed Goluch to make this a reality.